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Abstract: Childhood asthma is a common chronic condition.  Approximately five percent of all children 
in western countries are prescribed treatment with inhaled corticosteroids (ICS) to prevent asthma 
symptoms.  Current guidelines advocate titrating ICS dose to symptoms but this approach is not 
without problem, e.g. how to discern asthmatic from non-asthmatic symptoms?  And when to reduce 
ICS dose? This review describes the strengths and weaknesses of fractional exhaled nitric oxide 
(FENO) as an objective index for individualising asthma control in children.   Epidemiological and 
mechanistic evidence suggest that FENO should be a promising biomarker for eosinophilic airway 
inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not 
consistently found benefit from adding FENO to a symptom-based approach to ICS treatment in 
children.  There are a number of reasons why FENO has apparently failed to translate from promising 
biomarker to clinically useful tool, and one reason may be a lack of understanding of what merits a 
significant intrasubject change in FENO.  This review describes the rise and apparent fall of FENO as 
biomarker for asthma and then focuses on more recent evidence which suggest that FENO may prove 
to have a role in the management of childhood asthma. 
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2.1 The study of De Jongste is missing (AJRCCM 2009), although in this study 'usual care'was not very 'usual'. 
Also, Peirsman published a study in pediatr pulmonol 2013 on FENO monitoring.  
THANK YOU FOR POINTING OUT THESE PAPER WHICH HAVE BEEN OMITTED BUT NOW INCLUDED 
 
page 8: a meta-analysis with raw data of all studies is actually missing and might be interesting, as Petsky and 
all did not use original data from all studies. A meta-analysis (not on original data) that is missing (although in a 
low impact paper) is by Mahr et al, Asthma Allergy Proc 2013. 
THANK YOU FOR DRAWING MY ATTENTION TO THIS META-ANALYSIS (MAHR) WHICH IS NOW CITED 
 
3.1 although FeNO increases with height, this is in my opinion not a major problem, as most children with 
asthma are seen every 3 to 6 months, a period in which you do not expect spectacular growth. This might 
explain an increase of 5-10 ppb max. I feel seasonal influences, viral infections (which are not mentioned here) 
and intraperson variability are much more of a problem in interpreting longitudinal FeNO values. 
Intraindividual varaibilty as described by the author may be much bigger than fluctuations due to severity or 
control of disease. 
I HAVE AMMENDED THIS SECTION TO ACKNOWLEDGE THAT OVER THE SHORT TERM, CHANGE IN HEIGHT IS 
NOT LIKELY TO BE RELEVANT TO FENO MEASUREMENTS.  I HAVE ALSO ADDED VIRAL INFECTION AS A 
TEMPORARY INFLUENCE ON FENO VALUES. INTRAINDIVIDUAL VARIABILITY IS DISCUSSED IN SECTION 3.6 
 
3.2 As the author states, I do not think poor adherence in the dose titration studies was the case. In particular 
in the study by Szefler the primary outcome decrease spectacular after the run-in period, making this study 
even underpowered. Then even if adherence was not optimal in the referred studies, this would reflect daily 
practice and make the results of the studies more applicable to daily life.  
I AGREE 
 
3.3 Although I can follow the arguments of the author here, I do not think that a FENO driven treatment will be 
possible in an era where patient reported outcomes are becoming more and more important as primary 
outcomes.  However, the author may be right as 'the sputum eosinophil driven treatment' by Green et al in 
adults, led to less (severe) exacerbations in the treatment arm where treatment was adjusted to sputum 
eosinophils only.  
AGAIN I AGREE AND I THINK A BALANCED ARGUMENT IS PRESENTED HERE AS LATER IN THIS SECTION, THE 
TEXT SAYS “…THE POOR CORRELATION BETWEEN ASTHMA CONTROL AND FENO …. DOES QUESTION WHETHER 
ASTHMA TREATMENT CAN BE GUIDED ONLY BY FENO”   
 
3.5 Except for the discussion of cut offs, the 'reference values' could be debated. Maybe one should use 
'reference values' obtained from data in an asthmatic population with well-controlled asthma instead of a 
healthy population. This was nicely summarized by Peter Gibson in Clin Exp Allergy 2009: 'The algorithm 
decision points should be based on outcomes in the population of interest rather than the range of values in 
healthy people, and the algorithm used needs to provide a sufficiently different result to clinical decision 
making in order for there to be any discernible benefit.' I would certainly cite this paper, as this very nicely 
summarizes how to design exhaled NO studies. However, the problem may be that the range of what is normal 
in well-controlled asthmatics is too broad.  
THE PAPER BY PETER GIBSON IS CITED IN THIS SECTION (REF 62).  I HAVE POINTED THE READER IN THE 
DIRECTION OF THIS PAPER AND CLARIFIED THE DIFFERENCE BETWEEN KNOWING WHAT A “HIGH” ONE-OFF 
*Detailed Response to Reviewers
MEASUREMENT IS AND A HIGH MEASUREMENT RELATIVE TO PREVIOUS VALUES.  
 
A two weeks course of prednisone will lower FENO more than the optimal dose of inhaled corticosteroids and 
should not be the target in my opinion (Smith JACI 2009). On the other hand, FENO immediately after 
prednisone may not be the optimal value that can be obtained, as was shown for FEV1 (Lex, Pediatr Pulmonol 
2005). 
I HAVE INCLUDED THIS GOOD POINT, IE THAT ORAL STEROIDS MAY YIELD AN UNACHIEVEABLE FENO VALUE.  
 
Bullet 5 (page 16) Another reason why some studies did not show an effect of FENO monitoring and adjusting 
treatment on FENO was the fact that studies did not allow for step down if patients were symptomatic while 
having low FENO levels. Therefore, I would plea for stepping down if FENO is low despite symptoms.  
THANKS FOR THIS HELPFUL POINT WHICH I HAVE ADDED AS AN ADDITIONAL BULLET POINT 
 
An argument that is missing is that FENO driven treatment may be useless in children with concordant 
phenotypes (e.g. low FENO, low symptoms, normal FEV1 or high FENO, high symptoms and low FEV1), 
however, if there is discordancy between symptoms, FEV1 and FENO there might be a benefit of including 
FENO in treatment algorithms. 
I HAVE ADDED TEXT AT THE START OF SECTION 3.1 TO ADDRESS THIS POINT. 
 
Page 17: I suggest to do a meta-analysis with all original data.  
I HAVE DONE THIS 
 
Figure 1: I do not feel this adds much to the paper. 
I HAVE REMOVED THIS FROM THE MANUSCRIPT 
 
Figure 2 is not complete in my opinion. I would suggest to add poor inhaler technique and ongoing allergen 
exposure to the left upper part. Viral infections to the right upper part. Left lower quadrant: well controlled 
asthma? Right lower quadrant: coffee intake, after exercise, after flow-volume curves… 
I HAVE ADDED POOR INHALER TECHNIQUE, EXERCISE, SPIROMETRY AND VIRAL INFECTIONS AS SUGGESTED. I 
HAVE CHANGED EXPOSURE TO POLLEN AND POOR AIR QUALITY TO “ONGOING EXPOSURE TO INHALED 
ALLERGENS AND POOR AIR QUALITY” (TOP RIGHT).  CAFFEINE INTAKE INCREASES FENO IN CHILDREN.    
 
Table 2: References 68-72 are missing. Correlations with FEV1 are missing. There are many more papers on the 
correlations between asthma control (as assessed with ACT for example) and FENO, FEV1, PAQLQ etc.  
REFERENCES 68-72 (NOW REFERENCES 44-48) WERE CITED IN TABLE 2 BUT ARE NOW ALSO CITED IN THE TEXT 
(SECTION 3.1). I HAVE ADDED REFERENCES RELATING ENO TO FEV1.  THE REFERENCES USED WERE NOT 
INTENDED TO BE EXHAUSTIVE BUT TO ILLUSTRATE THE PRESENCE AND ABSENCE OF ASSOCIATIONS SO I HAVE 
NOT ADDED ANY FURTHER STUDIES TO THE REVIEW BUT AGREE THAT THERE ARE MANY MORE WHICH I 
COULD CITE. 
 
Table 3: add studies of De Jongste and Peirsman. One additional study was presented as an abstract at the ERS 
congress in 2013 by Voorend-van Bergen.  
THESE TWO PUBLISHED STUDIES HAVE BEEN INCLUDED IN THE TABLE.  GIVEN THE LACK OF DATA FROM THE 
ABSTRACT, I HAVE MENTIONED THE UNPUBLISHED STUDY IN THE TEXT AT THE END OF SECTION 2.1 BUT NOT 
INCLUDED THIS IN THE TABLE  
 
Table 4: I would not say that asthma exacerbation is 'independent of asthma'. 
I HAVE DELETED THIS ROW FROM THE TABLE. 
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Table 1.  Clinically important questions in asthma management where FENO may give insight 
 
Are these asthmatic symptoms in this child with asthma? 
Should treatment be stepped up with inhaled corticosteroids or alternative medications? 
When is it appropriate to step down inhaled corticosteroid treatment? 
When is it safe to stop treatment with inhaled corticosteroids? 
Table 1
Table 2.  Summary of the literature suggesting that exhaled nitric oxide (FENO) may or may 
not be a good biomarker for childhood asthma. 
Studies suggesting FENO may be a good 
biomarker for childhood asthma 
Studies suggesting FENO may NOT be a good 
biomarker for childhood asthma 
FENO is elevated in children with asthma 
13
 
 
FENO is elevated in atopic non-asthmatic 
children 
45
 
79
 and in adolescents whose 
asthma has remitted 
80
 
Exhaled nitric oxide is positively correlated 
with three hallmarks for asthma, sputum 
eosinophils 
44,81,82
 (r=0.5), FEV1
44
 and 
bronchial hyperresponsiveness (BHR) 
45
 
46
  
 
Exhaled NO is not related to FEV1 
45
 or 
BHR 
48
  
Exhaled nitric oxide is positively correlated 
with airway eosinophilia after two weeks 
treatment with oral corticosteroids (r=0.5) 
10
 
 
Elevated FENO is associated with poor 
asthma control (r=0.2) 
41-43
 
FENO is not correlated with asthma control
47
 
 
FENO rises after withdrawal of ICS and 
before symptoms relapse
18
 
FENO does not predict relapse after ICS 
withdrawal 
83
 
Treatment with inhaled corticosteroids reduces 
FENO in children with asthma 
68
.   
FENO remains elevated in some individuals 
despite treatment with ICS 
84,85
.   
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Table 3.  Details of the six randomised controlled trials comparing standard symptom-based asthma management against standard management 
plus exhaled nitric oxide (FENO) in children with asthma.   
Study Population details FENO Cut 
off(s) used  
Study design Primary outcome Secondary outcomes 
de Jongste
32
 Aged 6-18 attending 
academic centres or 
hospitals.  Atopic (by 
plasma IgE or skin 
prick test). Stable 
mild-moderate 
asthma.  151 
randomised. 
≥20 ppb for 
6-10 year 
olds 
≥25 ppb for 
>10 year olds 
30 week study, 
intervention arm 
made daily FENO 
measurements. 
Treatment 
reviewed each 3 
weeks by 
telephone, 
physiological 
testing 1, 3, 5 
months and at end 
of study 
Symptom free days 
during last 3 months 
of trial; this 
improved equally in 
both arms of the 
trial.  
No difference between control and 
intervention arm for ICS dose, 
FEV1, FENO or exacerbations.  
Peirsman
33
 Age range not stated.  
Mild to severe asthma 
attending hospital 
clinics. Atopic (by 
plasma IgE or skin 
prick testing).  99 
randomised 
≥20 ppb 52 week study.  
FENO and 
symptoms 
reviewed every 
three months 
Symptom free days; 
no difference 
between groups 
Exacerbation; reduced in 
intervention arm (18/49) compared 
to the control arm (35/50). 
Fritsch
27
 Aged 6-18 years. 52 
randomised.Attending 
hospital clinic.  Skin 
prick positive.  
Greater than  
or ≤20ppb 
6 month duration, 
assessed each 6 
weeks 
FEV1 – no 
difference 
Exacerbations, mid expiratory 
flows, control.  Mid expiratory 
flow 11 % higher in FENO group.  
Increased ICS doses (200 
microg/day) in FENO group.  
Petsky 
31
 Aged >4 years 81 
children invited 63 
≥ or less than 
10 ppb for 
12 month study, 
monthly visits for 
Exacerbation – 
FENO associated 
Quality of life and spirometry did 
not significantly differ between 
Table 3
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randomised.  
Attending hospital 
clinic.  
non atopic 
children 
≥ or less than 
12 ppb with 
one positive 
skin test 
≥ or less than 
20 ppb with 
more than 
one positive 
skin test 
four months and 
alternate months 
thereafter.  
with reduced 
exacerbations (19% 
versus 47%) 
groups 
Pijnenberg
30
 
 
Aged 5-18 years.  108 
screened 89 
randomised. 
Attending hospital 
clinic. Atopic asthma 
treated with ICS.  
Less than or 
≥30ppb 
12 month study 
with assessments 
each 3 months 
ICS dose.  No 
difference between 
groups. 
FENO group had improved PD20 
(1.3 doubling doses), lower FENO 
(geometric mean difference at end 
of study 32% lower) and trend for 
fewer exacerbations (20% versus 
39%) 
Pike
28
 Aged 6-17 years. 96 
screened, 90 
randomised.  
Attending hospital 
clinic with moderate-
severe asthma.   
≤15ppb 
15.1-24.9ppb 
≥25 ppb 
12 month study, 
assessed each 2 
months 
ICS dose and 
exacerbation.  No 
difference between 
groups. 
Spirometry, no difference between 
groups. 
Szeffler
26
 Aged 12-20 years.  
780 screened.  546 
randomised. Inner 
city area where ≥20% 
households below 
poverty level.  
0-20 
20.1-30 
30.1-40 
>40 
46 week duration 
assessments each 
6-8 weeks 
Number of days 
with symptoms.  No 
difference between 
FENO and control 
groups 
FENO group had:  
Mean increased fluticasone 
treatment 119 microg/day. 
10% reduction in proportion 
requiring OCS 
Among obese children 0.6 fewer 
days with symptoms.  For those 
with multiple positive skin tests (ie 
>9 out of 14 tested) 0.8 fewer days 
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with symptoms.  
  
Verini
29
 Aged 6-17 years.  64 
children. Referred to 
hospital and admitted. 
12 12 month study 
with assessments 
at baseline and 
after 6 and 12 
months 
Severity score 
(mean reduced 
significantly from 
1.1 to 0.6 and 0.8 
after 6 and 12 
months only in the 
FENO group).  
Exacerbation (mean 
number reduced 
from 2.0 to 1.0 and 
0.8 only in FENO 
group), treatment 
(unchanged in FENO 
group but some 
evidence of 
increased treatment 
in control arm). 
Spirometry – no difference 
Table 4.  Factors which are associated with changes in FENO in children independent of 
asthma 
 
Factor Approximate magnitude of effect 
Height Up to 1ppb rise per cm height gained 
24
 
Dietary exposures Short lived rise of up to 5-10ppb 
53,54
 
Allergen exposure Rise of up to 50% during birch pollen 
season 
56
 
Exposure to second hand smoke Reduction of 100% (26ppb for exposed 
children versus 56ppb)  
57
 or  absolute 
reduction of 10ppb 
58
 
Exposure to poor outdoor air quality Rise of approximately 1ppb 4 hours after 
each increase of 10mg/m
3
 fine particulate 
exposure (PM2.5) 
59
 
Genetic variations Variations in genes coding for NOS2 and 
NOS3 may lead to differences in FENO in 
adults of 10% 
86
 or 10ppb 
87
 but no 
association found for NOS1 variant and 
FENO in children 
88
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ABSTRACT  
Childhood asthma is a common chronic condition.  Approximately five percent of all 
children in western countries are prescribed treatment with inhaled corticosteroids (ICS) 
to prevent asthma symptoms.  Current guidelines advocate titrating ICS dose to 
symptoms but this approach is not without problem, e.g. how to discern asthmatic from 
non-asthmatic symptoms?  And when to reduce ICS dose? This review describes the 
strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index 
for individualising asthma control in children.  Epidemiological and mechanistic evidence 
suggest that FENO should be a promising biomarker for eosinophilic airway inflammation 
(a hall mark for asthma) but somewhat surprisingly, clinical trials in children have not 
consistently found benefit from adding FENO to a symptom-based approach to ICS 
treatment in children.  There are a number of reasons why FENO has apparently failed to 
translate from promising biomarker to clinically useful tool, and one reason may be a lack 
of understanding of what merits a significant intrasubject change in FENO.  This review 
describes the rise and apparent fall of FENO as biomarker for asthma and then focuses on 
more recent evidence which suggest that FENO may prove to have a role in the 
management of childhood asthma, and in particular preventing exacerbations. 
 
Keywords: Asthma, Control, Child, Exhaled Nitric Oxide, Randomised Clinical Trial 
  
3 
 
EDUCATIONAL AIMS 
 To summarise the literature from observational studies which support the role of 
fractional exhaled nitric oxide (FENO) as a biomarker for asthma control. 
 To summarise the results from clinical trials which have used FENO to guide 
asthma treatment. 
 To explore why there was an apparent failure to translate FENO from bench to 
bedside. 
 To explore how FENO might be used in the future management of childhood 
asthma 
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1. A HISTORICAL BACKDROP TO ASTHMA AND NITRIC OXIDE 
 
1.1 The search for an asthma control biomarker. Childhood asthma is a very common 
condition world wide
1
 and approximately five percent of all children in western countries 
are prescribed inhaled corticosteroids (ICS) to prevent asthma symptoms
2
.  Asthma 
remains a challenging condition to diagnose and manage in children (and adults) since 
there is no definition, diagnostic test or biomarker to objectively monitor disease control.  
Historically, several biomarkers have been evaluated as potential biomarkers for asthma 
control including peak flow, spirometry, bronchial hyperresponsiveness and eosinophil 
cationic protein but these tests all lack sufficient sensitivity and specificity.  This review 
will focus on the potential for fractional exhaled nitric oxide (FENO) to be a biomarker for 
childhood asthma.  This review will not explore the potential utility of FENO for 
diagnosing asthma which has been reviewed elsewhere
3,4
.  A as a simple rule low FENO 
(<10ppb) can be considered a good screen to exclude allergic asthma in children aged ≥ 
five years and concentrations of ≥19ppb might  have positive predictive value4 but the 
interpretation of higher FENO remains challenging and this is predominantly due to 
confounding by atopy which leads to elevated FENO independent of asthma. 
 
There is a pressing need for a biomarker for asthma management in children
5
 due to a 
number of clinically important questions to which there are currently no answers (table 
1).  Currently the management of asthma is driven by symptoms and at times can be 
based on trial and error.  One example of clinical uncertainty is the case of a child with 
asthma symptoms despite treatment with inhaled steroids – does the clinician increase 
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ICS dose or add in long acting beta agonist or leukotriene receptor antagonist?  Children 
with asthma also get non-asthmatic respiratory symptoms
6
 so how does the clinician 
deduce whether respiratory symptoms in a child with asthma are asthmatic or not?  Third 
and fourth clinical scenarios are the decision-making behind stepping down or stopping 
ICS treatment in a child with no asthma symptoms on ICS treatment?  Exhaled NO has 
the potential to give insight into these everyday clinical dilemmas.   
 
1.2. Exhaled nitric oxide and asthma control, a brief summary of the evidence. Until the 
late 1980s, nitric oxide was thought to be just a pollutant generated from burning fossil 
fuels, but was subsequently found to be important to cellular function in many human 
organs and in 1992 was voted molecule of the year by Science magazine. Nitric oxide, a 
simple diatomic molecule, proved to be important in cellular communication and was the 
substance previously known as endothelial derived relaxing factor, a potent vasodilator. 
Nitric oxide is produced by two enzymes.  Constitutive nitric oxide synthase (NOS) 
constantly produces NO at relatively low concentration and this activity is thought to be 
important to health and wellbeing; at low concentrations NO’s properties in the 
respiratory system may include antimicrobial, immune regulation and possibly 
bronchodilation.  The second enzymatic source of NO is inducible NOS which, on 
stimulation, can produce higher concentrations of NO compared to constitutive NOS 
which are associated with disease 
7-9
.  In the airways, higher concentrations of NO have 
no homeostatic role and are thought to be secondary to eosinophil inflammation
10
.  The 
presence of gaseous nitric oxide in human exhaled breath was first reported in 1993
11
 and 
shortly afterwards was found to be elevated in adults with asthma
12
; this observation was 
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replicated in children four years later 
13
.  A flurry of scientific activity relating exhaled 
nitric oxide to asthma was published during the early 2000s and this indicated both the 
potential 
14,15
 and the limitations 
16
 of using NO in exhaled breath as a biomarker for 
asthma (table 2).   
 
With the epidemiology and cellular/molecular work pointing to FENO being a potential 
biomarker for asthma control in children and a standard methodology agreed, a number 
of studies explored where FENO might be used in asthma management. One study 
demonstrated how rising exhaled nitric oxide concentration (using a threshold 
concentration of >22ppb) and rising airway eosinophilia (using % eosinophil count as a 
continuous variable) were independently predictive of failure to step down inhaled 
corticosteroids in children with stable asthma 
17
.  A second study measured FENO four 
weeks after cessation of ICS treatment and found that concentrations in excess of 49ppb  
had the best sensitivity (71%) and specificity (93%) for subsequent asthma relapse 
18
.  By 
2005 clinical trials were under way where FENO was applied to asthma management as an 
adjuvant to the standard symptom-based approach advocated by consensus guidelines. 
 
1.3. A standard methodology for measuring NO in exhaled breath. This was agreed by 
the American Thoracic and European Respiratory Societies and published in 1999
19
 and 
revised in 2005
20
.  One of the challenges in measuring NO in exhaled breath is flow 
dependence, i.e. at higher expiratory flows, concentrations are reduced and vice versa .  
The flow dependence of exhaled NO does give insight into the origin of elevated NO in 
an individual (broadly from the proximal or distal airways) by deriving flow independent 
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parameters.  Descriptions of derivation of flow independent parameters and their 
potential clinical relevance in children are available elsewhere 
21,22
.  The agreed standard 
was to measure the fractional exhaled nitric oxide at 50 ml/s.  Using this methodology, a 
child without asthma would typically have FENO of 8-10 parts per billion (ppb) 
23
 but 
concentrations might be up to 25 ppb 
24
. Not only was there evidence to support the 
paradigm that FENO was a biomarker for asthma control from epidemiological, 
observational and mechanistic studies, FENO measurements could be made quickly, with 
minimal discomfort, good reproducibility 
25
 and results were available within minutes. 
 
 
2. EXHALED NO AS A BIOMARKER FOR ASTHMA MANAGEMENT IN 
CHILDREN    
2.1. Results from clinical trials.  At the time of writing there have been at least eight trials 
published which explored the clinical utility of FENO in the management of asthma in 
children 
26-33
.  These randomised clinical trials compared standard symptom-based 
management against standard management plus FENO (rather than symptom based versus 
FENO based management) and each study used absolute FENO values to guide changes in 
treatment (rather than relative or personalised FENO values).  The clinical trials were 
undertaken by groups working independently and inevitably there is considerable 
heterogeneity between designs of the trials (table 3).  The lower age limit for inclusion 
varied between 5 and 12 years, one recruited from the community
26
 whilst the remainder 
recruited from hospital clinics 
27-33
and some only included atopic children with 
asthma
27,30,32,33
.  The absolute FENO values used as cut offs ranged between 10 and 40ppb, 
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some trials had only one cut off FENO value 
27,29,30,32,33
, whilst others had three or four 
FENO values to trigger escalation in asthma treatment 
26,28
 and one employed different 
single cut offs for an individual based on their atopic status
31
.  One study also included 
FEV1 in the decision making algorithm in addition to FENO 
27
. The primary outcome for 
the studies, upon which the power calculations were based, were varied and included ICS 
dose
28-30
 FEV1
27
, exacerbations
28,29,31
, severity
29
 and symptomatic 
32,33
. None of the 
studies observed improved asthma control among the FENO arms, three found reduced 
exacerbations 
26,29,31,33
, two found improved physiological measurements (i.e. spirometry 
27
and bronchial hyperresponsiveness 
30
),  two found increased doses of ICS among those 
randomised to FENO guided treatment 
26,27
 and one found reduced asthma severity over 
the course of the trial
29
.  One very recent study, published only in abstract form at the 
time of writing 
34
 reported symptoms free days in 280 children aged 4-18 years 
randomised to (i) symptom driven treatment (ii) web-based monthly monitoring and (iii) 
symptom based treatment plus 4 monthly FENO measurement; here symptom free days 
increased marginally the FENO arm. Systematic reviews and meta-analyses using data 
from some of these studies have concluded that the evidence does not support the 
addition of FENO to standard symptom-based management of asthma for day-to-day 
control 
35-37
 but one finds evidence for FENO leading to reduced exacerbations
37
.  In 
contrast, at least one expert group argues that FENO has an important role in the 
management of asthma
38
.  Between evidence synthesis
35-37
 and expert opinion
38
, a recent 
report from the National Institute for Clinical Efficacy in the UK 
39
 has suggested that “it 
could be argued that the available evidence does point towards some benefit to the 
technology [FENO measurement]” and cites limitations in the current literature as 
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including “cut off values [which] are highly variable and largely based on derivation 
studies” and “unclear step-up/step-down protocols”. 
2.2 Meta-analysis. Although this is not a systematic review, the eight papers identified in 
section 2.1 are likely to represent most papers published in this area and meta-analysis 
was undertaken using standard software was used (Review manager 5.2).  The outcomes 
were (i) risk for an individual requiring at least once course of oral corticosteroids. 
Details of individuals requiring ≥1 course of OCS were provided by the author of one 
study 
28
 and was not available for a second 
29
.  Meta-analysis of seven studies 
demonstrated that risk for an individual having an exacerbation requiring OCS was 
reduced by treatment guided by FENO plus symptoms versus symptoms alone, odds ratio 
0.67 [95%  CI 0.51, 0.88]  (figure 1).  One study
26
 contributed almost two thirds of data 
for this analysis and substantially influences the overall result from the meta analysis.   
(ii) risk for an individual having any exacerbation (however defined in the study design). 
The risk for an individual having ≥1 exacerbation of any type could not be determined 
two studies (one reported total number of exacerbations
27
 and a second did not report 
exacerbations
29
); treatment with FENO plus symptoms was associated with an identical 
reduction in risk compared to symptoms only as in (i) above (OR 0.67 [95% CI 0.51, 
0.88]. 
 (iii) ICS dose at the end of the study.  Analysis for ICS dose at end of study was 
complicated by data being presented as median and interquartile range whereas the 
software (widely regarded as the gold standard) requires mean and standard deviation 
values.  Data were transformed to mean and standard deviation 
40
 assuming that 25
th
 and 
75
th
 centile values were low and high end of the range; these assumptions can be easily 
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challenged and should be considered when interpreting the results from this meta-
analysis.  Data were not available for three studies of which two
29,
 
30
 reported (in the text) 
no increase in dose and one
26
 which reported higher dose ICS (mean difference 119 
microg budesonide equivalent [95% CI 49, 189]) associated with treatment guided by 
FENO.  Among the remaining 5 studies there was an overall mean increase in ICS dose of 
106 microg BUD equivalent [95% CI 75, 138], figure 2. The magnitude of this 
association is consistent with the one large study which dominated the meta analysis
26
 
and FENO guided treatment seems to be associated with an increased in ICS dose of 
approximately 100 microg BUD equivalent.  In addition to the assumptions about mean 
and SD values (which resulted in an apparent dose reduction for the FENO arm of the 
study by de Jongste et al 
32
where median values in the two arms were equal at 200 
microg), there is an additional caveat to these results; the results are heterogeneous and 
when adjusted for (using random effects) the mean increase in ICS is 88 microg BUD 
equivalent [95% CI -10, 86]. 
3. WHY MIGHT EXHALED NO NOT BE A USEFUL BIOMARKER? 
3.1 Exhaled NO is poorly specific for asthma. Elevated NO is a biomarker for 
eosinophilic inflammation rather than for asthma per se and this indirect relationship with 
asthma may explain why some studies find FENO is an index of asthma control scores
41-43
, 
FEV1
44
 and bronchial hyper responsiveness (BHR) 
45
 
46
, but FENO is not universally 
associated with control
47
, FEV1
45
 or BHR
48
.  There is the possibility that FENO is a more 
accurate index of asthma control for some individuals, eg those with atopy, or for 
individuals where there is discordance between symptoms and FEV1. Eosinophilic 
inflammation may be asymptomatic and this most likely explains the relationship 
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between FENO and atopy and bronchial hyperreactivity in children without asthma 
45,49,46,50
.  It has been proposed that FENO is merely an index of atopy, i.e. a skin prick test, 
since concentrations are positively correlated with the number of skin tests 
45
 and age at 
onset of atopy 
51
 but this is probably over simplistic since FENO does change acutely after 
exposure to oral corticosteroid treatment
52
, certain foods
53,54
, exercise 
55
 and pollen
56
. 
What has been recognised is that factors other than asthma may acutely and chronically 
influence NO production in children (table 4, figure 3).  Male gender and increasing 
height are consistently associated with modest increase in FENO concentrations and, 
although children are not likely to grow by more than a few cm between clinic visits, the 
association with anthropometric measurements challenges the logic behind having single 
FENO values to trigger changes in ICS throughout childhood; a teenager will grow by as 
much as 30cm during puberty and their FENO value will rise by approximately 5-10 ppb.  
As an aside, the association between height and increased FENO is an interesting 
observation since a measurement of concentration should adjust for size so this is not 
simply bigger people producing more NO.  Dietary exposures have been associated with 
acute changes in FENO in children 
53,54
 but these changes are short-lived and of a small 
magnitude. Nitric oxide is derived from the amino acid L-arginine and ingestion of a dose 
of L-arginine equivalent to two chicken breasts is associated with a 5 ppb rise in FENO 
which lasts one hour
54
.   Caffeine induces nitric oxide synthase and ingestion of a large 
drink of cola leads to a 9ppb increase in FENO after 30 minutes which resolves after one 
hour. 
53
  Inhaled exposures such as second hand tobacco smoke 
57
 
58
 and poor outdoor air 
quality
59
 are associated with increased FENO but it is not known how long these changes 
last for.  Respiratory infection with virus temporarily affects FENO values but the nature 
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of this association is not clear; FENO values are reduced in infants with respiratory 
syncitial virus
60
  or rhinitis 61 but in adults with experimentally induced rhinovirus 
infection, FENO rises by approximately 5ppb 
62
. There is little direct evidence of the effect 
of viral infection in children; indirect evidence comes from observations made during 
exacerbations, precipitated by rhinovirus, which are associated with elevated FENO
52,63
. 
The apparently inconsistent findings between virus infection and changing FENO might 
reflect differences in the host response to different virus which may be age related and 
also the retention of NO within secretions.  Further evidence of almost continuous but 
small fluctuations in FENO is evidenced by the diurnal variability in concentrations
64
; 
concentrations are less than 1 ppb higher in the morning compared to the afternoon.   In 
addition to variability over minutes and hours, FENO is elevated in children with asthma 
during periods when grass pollen exposure is present 
41,56
 and also is elevated during the 
autumn (when moulds cast spores) for those exposed to indoor moulds 
43
.  Children with 
hayfever have elevated FENO
65 
and concentrations become particularly elevated during 
the spring when compared to those without hayfever 
43
.  In addition to the factors 
described in table 4 and figure 3, intrasubject variability in FENO measurements may also 
be introduced by the apparatus itself.  As with all analytical processes, there is variability 
in repeated measurements using the same apparatus and this variability can be reduced by 
measuring two or three FENO values and reporting the mean value 
20
 but this requires time 
and also costs money.  Further apparatus-dependent variability arises when different 
methods to derive NO are used; one study found an intrasubject difference of 4ppb 
between devices made by the same manufacturer
66
.  Intrasubject variability becomes 
considerably greater when apparatus from different manufacturers are used
67
 where a 
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typical difference might be 8ppb but range between -12 and +28ppb.  At present it seems 
sensible to make repeated measurements for a given individual using the same apparatus.  
 
3.2 Trials were confounded by poor adherence with inhaled corticosteroid treatment. 
Adherence to ICS treatment is crucial to the interpretation of elevated FENO, as it 
currently is for standard symptom-based asthma management.  Elevated FENO is 
associated with poor asthma control 
41-43
 and poor adherence with ICS treatment 
26,68
, 
whereas increasing ICS treatment leads to reduced FENO 
68
.  Adherence to treatment is 
always a challenge to measure in asthma, one paper found that typical FENO 
concentrations for adolescents with adherence was >50% was 24 ppb and was 31ppb for 
those with <50% compliance 
26
.  A second study of 17 children found that compliance 
with ICS of between 75 and 100% was associated with a relative reduction in FENO of 50-
100% whereas compliance below 75% was associated with changes in FENO of less that 
50% 
68
.  Observations of heterogeneity in FENO response to ICS 
69,70
 might reflect the 
presence of individuals with high FENO but little airway eosinophilia, a phenomenon seen 
in adults
71
 but not described in children, or heterogeneity in adherence to ICS treatment.  
Although there is most likely to be incomplete adherence to ICS in the clinical trials, 
asthma outcomes improved in both FENO and standard arms of most trials suggesting that 
adherence was generally good. 
3.3 Wrong study design.  The clinical trials which have been completed in children to 
date all compared standard symptom-based treatment versus standard treatment plus 
FENO and perhaps trials should compare symptom-based treatment versus FENO only 
treatment.  This bold study design has only been used in one trial of adult patients
72
 and 
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found that FENO guided treatment was associated with reduced ICS doses and a non-
significant trend for reduced symptoms compared to symptom based management.  The 
poor correlation between asthma control and FENO reported in some studies
41-43
 and the 
lack of correlation in at least one study
47
 does question whether asthma treatment can be 
guided only by FENO.  On the one hand, FENO and symptoms measure different outcomes 
and therefore an algorithm which captures both outcomes might be better than either 
alone.  A more conservative approach might argue that there is a too much of a leap of 
faith involved in using FENO to guide treatment, and the symptom-based approach is 
patient-centred and therefore symptoms should predominate as the ultimate trigger for 
changing asthma treatment. 
3.4 Insufficient power.  Although studies justified their sample size by a power 
calculation, descriptions of the power calculations do not include a mean or median FENO 
value and associated variability.  Pragmatically, only two published studies randomised 
more than 100 children
26
 
32
 so it is possible that the remaining studies may have been 
underpowered.  
3.5 Wrong cut offs used.  Although increased FENO is associated with adverse asthma 
outcomes in children, the definition of what is “increased” remains unclear.   .  Evidence 
from population studies suggests that concentrations of >35ppb in children are “high” 38 
but the question “what is a significant change in FENO for an individual?” remains poorly 
understood and has been explored in detail elsewhere 
73
. One early study suggested that a 
change of 4 ppb might be clinically significant
74
 but, as table 4 demonstrates, there are 
many factors other than asthma which can acutely change FENO by an order of at least 
4ppb.  Furthermore, a rise of 4ppb might be important in a child whose previous FENO 
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was 10ppb but not for a second individual whose FENO was 20ppb and relative change in 
FENO seems a more meaningful method for interpreting repeated measurements.   Recent 
studies in adults have suggested that a relative change of <30% is unlikely to be clinically 
relevant 
75
 and a change from poor control to good control was associated with a FENO 
reduction of greater than 35% 
76
.  Having a “significant” magnitude of change in FENO of 
30-35% would be consistent with a clinically meaningful change in bronchial 
hyperreactivity (a hallmark for asthma and correlated with FENO) of half a doubling dose 
77
.  In children, a FENO rise of 60% from baseline (with 95% confidence intervals of 
approximately 25, 140) was associated with an exacerbation 
63
 and by extrapolation, a 
rise in FENO of less than 60% might be indicative of increasing symptoms. A clinical 
practical guideline published by the American Thoracic Society in 2011 
38
 acknowledged 
a weak evidence base and cautiously recommended that a rise in FENO of >20% or (in 
children) >20ppb may be significant and that a minimally important reduction in FENO 
was >20% for those with a FENO of ≥50ppb and <10ppb for those for those with lower 
values.  In the adult literature there has been interest in expressing FENO as a percentage 
of predicted but this option is losing favour, mostly due to lack of precision and to 
differences between reference populations raising the question of which reference is the 
best for a given population? A fourth method to express FENO is a as percentage of lowest 
value and is measured after a two week course of oral corticosteroids, but this has an 
associated morbidity, might yield a low FENO value which cannot be achieved with ICS 
treatment and should be reserved for use only in special cases under expert supervision. 
Of the four methods described, percentage difference seems best suited for 
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individualising treatment since this recognises the relatively wide range of values within 
a population of children.    
3.6 Insight into intrasubject variability. One recent study has given insight into the 
question “what is a significant change in FENO?” 
43
.  178 children were recruited, of 
whom 47 had asthma, in a community-based observational study where FENO was 
measured over six two-month intervals.  The difference between paired FENO 
measurements was expressed as an absolute value and limits of agreement. As might be 
expected, the limits of agreement for paired FENO measurements were greater for those 
with higher initial concentrations.  Average FENO values were stable over eight months 
but did become significantly higher over a ten month interval, presumably due to the 
children becoming taller.  Asthma was associated with elevated FENO in this population 
(27ppb versus 10 ppb for non-asthmatic) but when both time and baseline FENO value 
were considered, asthma was not independently associated with change in FENO value. 
As a rough rule of thumb, the authors suggested that FENO values may rise by up to 200% 
of the previous measurements over two to four months, independently of asthma.  For 
example, in the 40 children with initial FENO between 11 and 20 ppb (median value 
14ppb) the upper limits of agreement for measurements taken at a two and four month 
interval were +22ppb and +14 ppb respectively.  As might be expected over time (and 
regression to the mean), low initial FENO concentrations became higher whilst higher 
concentrations became lower; thus the lower limits of agreement over two and four 
months for children whose initial FENO was 21-30 ppb were -19 and -25ppb.  In keeping 
with the suggestion that a more permissive approach to interpretation of FENO values, a 
more liberal algorithm which allowed FENO concentrations to rise by up to 100% (from 
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16 to 29ppb) was found to be effective in reducing exacerbations and improving quality 
of life among pregnant women 
78
. 
In addition to describing variability in FENO over time, this study related FENO to asthma 
control (both present and future) and also to environmental exposures which might affect 
FENO values 
43
.  There was weak correlation between FENO and current and future asthma 
control measured over a four month interval (correlation coefficient approximately 0.2).  
Compared with maintained good asthma control over two months, children who were 
poorly controlled but became well controlled had elevated FENO; in contrast, neither 
those who had good asthma control which became poorly controlled nor those whose 
asthma control remained poor had elevated FENO.  These observations suggested that 
elevated FENO is an index of poor current control but not poor control in two month’s 
time.  Additionally the findings suggested that the mechanism for persistently poorly 
controlled symptoms in children with asthma may not involve eosinophilic airway 
inflammation. 
 
Future research directions - so where do we go beyond 2014 with FENO? 
It is too early to consign FENO to the dust bin where failed biomarkers for asthma are 
placed.  There is still sufficient evidence to indicate that FENO may have a role in helping 
to address the current situation where there are too many children treated with 
inappropriately high doses of inhaled corticosteroids and conversely, too many children 
with poorly controlled asthma whose quality of life can be improved with ICS treatment. 
The inconsistency between the epidemiology and mechanistic studies (supportive of a 
role for FENO in asthma management) and the clinical trials to date (which are generally 
  
18 
 
not supportive of adding FENO to standard symptom-based management) suggests either 
FENO lacks precision or we have not properly understood how to interpret FENO as a 
clinical tool. Time will show whether FENO does have role or not in the management of 
childhood asthma.  If FENO does prove to have a role in the management of childhood 
asthma then clinicians will have to place trust in FENO since guidelines will have to use 
FENO to step treatment down as well as up.  Now that insight is being gained into what 
merits a significant change in FENO, clinical trials are needed which test cut offs to 
treatment algorithms.  Future clinical trials designed to use FENO to improve asthma 
outcomes might consider the following: 
1. Comparing symptom based management and FENO only based management.  This 
might follow in the success of trials comparing symptoms versus FENO plus 
symptoms; the apparent failure of previous studies will understandably make 
clinicians very cautious in using only FENO to guide treatment.   
2. Careful attention to treatment adherence.  This needs to be integral to clinical 
trials since poor adherence has great potential to mask any true clinical benefit but 
in the long term, FENO may prove to give the clinician insight into adherence.   
3. What is the “best” outcome.  At present, the evidence would suggest that FENO 
may have a greater influence in reducing exacerbations rather than improving 
day-to-day control of symptoms.  It is possible that one algorithm may lead to 
better control and another to fewer exacerbations for a given individual. On a 
practical note, having symptom control as an outcome and part of the algorithm is 
a potential flaw in study design. 
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4. Absolute versus relative FENO values.  There is sufficient evidence to categorise 
individuals as having high FENO on study entry but more work is required in 
establishing whether cut offs for second and subsequent FENO values should be 
absolute or percent of previous values.  
5. Algorithms could use FENO to guide treatment step up options for individuals with 
uncontrolled asthma despite compliance with ICS treatment, i.e. to further 
increase ICS or use alternative “add ons”, as has been applied in adults78. 
6. Algorithms could use FENO to step down ICS treatment, even when (non-
asthmatic) symptoms are present. 
7. Clinical setting. Childhood asthma is a condition which is mostly managed in the 
community and trial design should ideally reflect this and aspire to an ideal of 
easily delivered personalised treatment algorithms 
8.  Preschool children. Methodologies are required to allow FENO to be measured in 
younger children – currently FENO can be measured in children aged 5-6 years  
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FIGURE LEGENDS 
 
Figure 1.  Summary of the asthma-dependent and independent factors associated with 
increased or reduced concentrations of exhaled nitric oxide (FENO). 
 
Figure 2.  A forest plot comparing the effect on exacerbations requiring oral 
corticosteroid treatment where maintenance treatment is driven by exhaled nitric oxide 
(ENO) and symptoms versus symptoms alone. 
 
Figure 3. A forest plot comparing the effect on inhaled corticosteroid dose at  the time of 
study exit where maintenance treatment is driven by exhaled nitric oxide (ENO) and 
symptoms versus symptoms alone. 
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ABSTRACT  
Childhood asthma is a common chronic condition.  Approximately five percent of all 
children in western countries are prescribed treatment with inhaled corticosteroids (ICS) 
to prevent asthma symptoms.  Current guidelines advocate titrating ICS dose to 
symptoms but this approach is not without problem, e.g. how to discern asthmatic from 
non-asthmatic symptoms?  And when to reduce ICS dose? This review describes the 
strengths and weaknesses of fractional exhaled nitric oxide (FENO) as an objective index 
for individualising asthma control in children.   Epidemiological and mechanistic 
evidence suggest that FENO should be a promising biomarker for eosinophilic airway 
inflammation (a hall mark for asthma) but somewhat surprisingly, clinical trials in 
children have not consistently found benefit from adding FENO to a symptom-based 
approach to ICS treatment in children.  There are a number of reasons why FENO has 
apparently failed to translate from promising biomarker to clinically useful tool, and one 
reason may be a lack of understanding of what merits a significant intrasubject change in 
FENO.  This review describes the rise and apparent fall of FENO as biomarker for asthma 
and then focuses on more recent evidence which suggest that FENO may prove to have a 
role in the management of childhood asthma and in particular preventing exacerbations. 
 
Keywords: Asthma, Control, Child, Exhaled Nitric Oxide, Randomised Clinical Trial 
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EDUCATIONAL AIMS 
 To summarise the literature from observational studies which support the role of 
fractional exhaled nitric oxide (FENO) as a biomarker for asthma control. 
 To summarise the results from clinical trials which have used FENO to guide 
asthma treatment. 
 To explore why there was an apparent failure to translate FENO from bench to 
bedside. 
 To explore how FENO might be used in the future management of childhood 
asthma 
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1. A HISTORICAL BACKDROP TO ASTHMA AND NITRIC OXIDE 
 
1.1 The search for an asthma control biomarker. Childhood asthma is a very common 
condition world wide
1
 and approximately five percent of all children in western countries 
are prescribed inhaled corticosteroids (ICS) to prevent asthma symptoms
2
.  Asthma 
remains a challenging condition to diagnose and manage in children (and adults) since 
there is no definition, diagnostic test or biomarker to objectively monitor disease control.  
Historically, several biomarkers have been evaluated as potential biomarkers for asthma 
control including peak flow, spirometry, bronchial hyperresponsiveness and eosinophil 
cationic protein but these tests all lack sufficient sensitivity and specificity.  This review 
will focus on the potential for fractional exhaled nitric oxide (FENO) to be a biomarker for 
childhood asthma.  This review will not explore the potential utility of FENO for 
diagnosing asthma which has been reviewed elsewhere
3,4
.  A as a simple rule low FENO 
(<10ppb) can be considered a good screen to exclude allergic asthma in children aged ≥ 
five years and concentrations of ≥19ppb might  have positive predictive value4 but the 
interpretation of higher FENO remains challenging and this is predominantly due to 
confounding by atopy which leads to elevated FENO independent of asthma. 
 
There is a pressing need for a biomarker for asthma management in children
5
 due to a 
number of clinically important questions to which there are currently no answers (table 
1).  Currently the management of asthma is driven by symptoms and at times can be 
based on trial and error.  One example of clinical uncertainty is the case of a child with 
asthma symptoms despite treatment with inhaled steroids – does the clinician increase 
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ICS dose or add in long acting beta agonist or leukotriene receptor antagonist?  Children 
with asthma also get non-asthmatic respiratory symptoms
6
 so how does the clinician 
deduce whether respiratory symptoms in a child with asthma are asthmatic or not?  Third 
and fourth clinical scenarios are the decision-making behind stepping down or stopping 
ICS treatment in a child with no asthma symptoms on ICS treatment?  Exhaled NO has 
the potential to give insight into these everyday clinical dilemmas.   
 
1.2. Exhaled nitric oxide and asthma control, a brief summary of the evidence. Until the 
late 1980s, nitric oxide was thought to be just a pollutant generated from burning fossil 
fuels, but was subsequently found to be important to cellular function in many human 
organs and in 1992 was voted molecule of the year by Science magazine. Nitric oxide, a 
simple diatomic molecule, proved to be important in cellular communication and was the 
substance previously known as endothelial derived relaxing factor, a potent vasodilator. 
Nitric oxide is produced by two enzymes.  Constitutive nitric oxide synthase (NOS) 
constantly produces NO at relatively low concentration and this activity is thought to be 
important to health and well being; at low concentrations NO’s properties in the 
respiratory system may include antimicrobial, immune regulation and possibly 
bronchodilation.  The second enzymatic source of NO is inducible NOS which, on 
stimulation, can produce higher concentrations of NO compared to constitutive NOS 
which are associated with disease 
7-9
.  In the airways, higher concentrations of NO have 
no homeostatic role and are thought to be secondary to eosinophil inflammation
10
.  The 
presence of gaseous nitric oxide in human exhaled breath was first reported in 1993
11
 and 
shortly afterwards was found to be elevated in adults with asthma
12
; this observation was 
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replicated in children four years later 
13
.  A flurry of scientific activity relating exhaled 
nitric oxide to asthma was published during the early 2000s and this indicated both the 
potential 
14,15
 and the limitations 
16
 of using NO in exhaled breath as a biomarker for 
asthma (table 2).   
 
With the epidemiology and cellular/molecular work pointing to FENO being a potential 
biomarker for asthma control in children and a standard methodology agreed, a number 
of studies explored where FENO might be used in asthma management. One study 
demonstrated how rising exhaled nitric oxide concentration (using a threshold 
concentration of >22ppb) and rising airway eosinophilia (using % eosinophil count as a 
continuous variable) were independently predictive of failure to step down inhaled 
corticosteroids in children with stable asthma 
17
.  A second study measured FENO four 
weeks after cessation of ICS treatment and found that concentrations in excess of 49ppb  
had the best sensitivity (71%) and specificity (93%) for subsequent asthma relapse 
18
.  By 
2005 clinical trials were under way where FENO was applied to asthma management as an 
adjuvant to the standard symptom-based approach advocated by consensus guidelines. 
 
1.3. A standard methodology for measuring NO in exhaled breath. This was agreed by 
the American Thoracic and European Respiratory Societies and published in 1999
19
 and 
revised in 2005
20
.  One of the challenges in measuring NO in exhaled breath is flow 
dependence, i.e. at higher expiratory flows, concentrations are reduced and vice versa 
(figure 1)..  The flow dependence of exhaled NO does give insight into the origin of 
elevated NO in an individual (broadly from the proximal or distal airways) by deriving 
  
7 
 
flow independent parameters.  Descriptions of derivation of flow independent parameters 
and their potential clinical relevance in children are available elsewhere 
21,22
.  The agreed 
standard was to measure the fractional exhaled nitric oxide at 50 ml/s.  Using this 
methodology, a child without asthma would typically have FENO of 8-10 parts per billion 
(ppb) 
23
 but concentrations might be up to 25 ppb 
24
. Not only was there evidence to 
support the paradigm that FENO was a biomarker for asthma control from 
epidemiological, observational and mechanistic studies, FENO measurements could be 
made quickly, with minimal discomfort, good reproducibility 
25
 and results were 
available within minutes. 
 
 
2. EXHALED NO AS A BIOMARKER FOR ASTHMA MANAGEMENT IN 
CHILDREN    
2.1. Results from clinical trials.  At the time of writing there have been at least eightsix 
trials published which explored the clinical utility of FENO in the management of asthma 
in children 
26-33
.  These randomised clinical trials compared standard symptom-based 
management against standard management plus FENO (rather than symptom based versus 
FENO based management) and each study used absolute FENO values to guide changes in 
treatment (rather than relative or personalised FENO values).  The clinical trials were 
undertaken by groups working independently and inevitably there is considerable 
heterogeneity between designs of the trials (table 3).  The lower age limit for inclusion 
varied between 5 and 12 years, one recruited from the community
26
 whilst the remainder 
recruited from hospital clinics 
27-33
and some only included atopic children with 
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asthma
27,30,32,33
.  The absolute FENO values used as cut offs ranged between 10 and 
40ppb, some trials had only one cut off FENO value 
27,29,30,32,33
, whilst others had three or 
four FENO values to trigger escalation in asthma treatment 
26,28
 and one employed 
different single cut offs for an individual based on their atopic status
31
.  One study also 
included FEV1 in the decision making algorithm in addition to FENO 
27
. The primary 
outcome for the studies, upon which the power calculations were based, were varied and 
included ICS dose
28-30
 FEV1
27
, exacerbations
28,29,31
, severity
29
 and symptomatic 
32,33
. 
None of the studies observed improved asthma control among the FENO arms, three found 
reduced exacerbations 
26,29,31,33
, two found improved physiological measurements (i.e. 
spirometry 
27
and bronchial hyperresponsiveness 
30
),  and two found increased doses of 
ICS among those randomised to FENO guided treatment 
26,27
 and one found reduced 
asthma severity over the course of the trial
29
.  One very recent study, published only in 
abstract form at the time of writing 
34
 reported symptoms free days in 280 children aged 
4-18 years randomised to (i) symptom driven treatment (ii) web-based monthly 
monitoring and (iii) symptom based treatment plus 4 monthly FENO measurement; here 
symptom free days increased marginally the FENO arm. Systematic reviews and meta-
analyses using data from some of these studies have concluded that the evidence does not 
support the addition of FENO to standard symptom-based management of asthma for day-
to-day control 
35-37
 but one finds evidence for FENO leading to reduced exacerbations 
37
.  
In contrast, at least one expert group argues that FENO has an important role in the 
management of asthma
38
.  Between evidence synthesis
35-37
 and expert opinion
38
, a recent 
report from the National Institute for Clinical Efficacy in the UK 
39
 has suggested that “it 
could be argued that the available evidence does point towards some benefit to the 
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technology [FENO measurement]” and cites limitations in the current literature as 
including “cut off values [which] are highly variable and largely based on derivation 
studies” and “unclear step-up/step-down protocols”. 
2.2 Meta analysis. Although this is not a systematic review, the eight papers identified in 
section 2.1 are likely to represent most papers published in this area and meta analysis 
was undertaken.  Standard software was used (Review manager 5.2).  The outcomes were 
(i) risk for an individual requiring at least once course of oral corticosteroids. Details of 
individuals requiring ≥1 course of OCS were provided by the author of one study 28 and 
was not available for a second 
29
.  Meta-analysis of these seven studies demonstrated that 
risk for an individual having an exacerbation was reduced by treatment guided by FENO 
plus symptoms versus symptoms alone, odds ratio 0.67 [95%  CI 0.51, 0.88]  (figure 1).  
One study
26
 contributed almost two thirds of data for this analysis and therefore 
substantially influences the overall result from the meta analysis.  Overall, there is a 
reduction in exacerbations requiring OCS treatment where asthma treatment is informed 
by both FENO and symptoms   
(ii) risk for an individual having any exacerbation (however defined in the study design). 
The risk for an individual having ≥1 exacerbation of any type could not be determined 
two studies (one reported total number of exacerbations
27
 and a second did not report 
exacerbations 
29
); treatment with FENO plus symptoms was associated with an identical 
reduction in risk compared to symptoms only as for need for OCS (OR 0.67 [95% CI 
0.51, 0.88]. 
 (iii) ICS dose at the end of the study.  Analysis for ICS dose at end of study was 
complicated by data being presented as median and interquartile range whereas the 
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software (widely regarded as the gold standard) requires mean and standard deviation 
values.  Data were transformed to mean and standard deviation 
40
 assuming that 25
th
 and 
75
th
 centile values were low and high end of the range; these assumptions can be easily 
challenged and should be considered when interpreting the results from this meta 
analysis.  Data were not available for three studies of which two
29,
 
30
 reported (in the text) 
no increase in dose and one
26
 reported higher dose ICS (mean difference 119 microg 
budesonide equivalent [95% CI 49, 189]) associated with treatment guided by FENO.  
Among the remaining 5 studies there was an overall mean increase in ICS dose of 106 
microg BUD equivalent [95% CI 75, 138], figure 2. The magnitude of this association is 
consistent with the one large study which dominated the meta analysis
26
 and FENO guided 
treatment seems to be associated with an increased in ICS dose of approximately 100 
microg BUD equivalent.  In addition to the assumptions about mean and SD values 
(which resulted in an apparent dose reduction for the FENO arm of the study by de 
Jongste et al 
32
when median values in the two arms were equal at 200 microg), there is an 
additional caveat to these results; the results are heterogeneous and when adjusted for 
(i.e. random effects) the mean increase in ICS is 88 microg BUD equivalent [95% CI -10, 
86]. 
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3. WHY MIGHT EXHALED NO NOT BE A USEFUL BIOMARKER? 
3.1 Exhaled NO is poorly specific for asthma. Elevated NO is a biomarker for 
eosinophilic inflammation rather than for asthma per se and this indirect relationship with 
asthma may explain why some studies find FENO is an index of asthma control scores
41-43
, 
FEV1
44
 and bronchial hyper responsiveness (BHR) 
45
 
46
, FENO is not universally 
associated with control
47
, FEV1
45
 or BHR
48
.  There is also the possibility that FENO is a 
more accurate index of asthma control for some individuals, eg those with atopy, or for 
individuals where there is discordance between symptoms and FEV1. Eosinophilic 
inflammation may be asymptomatic and this most likely explains the relationship 
between FENO and atopy and bronchial hyperreactivity in children without asthma 
45,49,46,50
.  It has been proposed that FENO is merely an index of atopy, ie a skin prick test, 
since concentrations are positively correlated with the number of skin tests 
45
 and age at 
onset of atopy 
51
 but this is probably over simplistic since FENO does change acutely after 
exposure to oral corticosteroid treatment
52
, certain foods
53,54
, exercise 
55
 and pollen
56
. 
What has been recognised is that factors other than asthma may acutely and chronically 
influence NO production in children (table 4, figure 12).  Male gender and increasing 
height are consistently associated with modest increase in FENO concentrations and, 
although children are not likely to grow by more than a few cm between clinic visits, the 
association with anthropometric measurements challenges the logic behind having single 
FENO values to trigger changes in ICS throughout for  childhoodchildren; a teenager will 
grow by as much as 30cm during puberty and their FENO value before puberty will rise 
by approximately 5-10 ppbbe of little relevance post puberty.  As an aside, the 
association between height and increased FENO is an interesting observation since a 
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measurement of concentration should adjust for size so this is not simply bigger people 
producing more NO.  Dietary exposures have been associated with acute changes in FENO 
in children 
53,54
 but these changes are short-lived and of a small magnitude. Nitric oxide is 
derived from the amino acid L-arginine and ingestion of a dose of L-arginine equivalent 
to two chicken breasts is associated with a 5 ppb rise in FENO which lasts one hour
54
.   
Caffeine induces nitric oxide synthase and ingestion of a large drink of cola leads to a 
9ppb increase in FENO after 30 minutes which resolves after one hour. 
53
  Inhaled 
exposures such as second hand tobacco smoke 
57
 
58
 and poor outdoor air quality
59
 are 
associated with increased FENO but it is not known how long these changes last for.  
Respiratory infection with virus temporarily affects FENO values but the nature of this 
association is not clear; FENO values are reduced in infants with respiratory syncitial 
virus
60
  or rhinitis 61 but in adults with experimentally induced rhinovirus infection, FENO 
rises by approximately 5ppb 
62
. There is little direct evidence of the effect of viral 
infection in children; indirect evidence comes from observations made during 
exacerbations, precipitated by rhinovirus, which are associated with elevated FENO
52,63
. 
The apparently inconsistent findings between virus infection and changing FENO might 
reflect differences in the host response to different virus which may be age related and 
also the retention of NO within secretions.  Further evidence of almost continuous but 
small fluctuations in FENO is evidenced by the diurnal variability in concentrations
6463
; 
concentrations are less than 1 ppb higher in the morning compared to the afternoon.   In 
addition to variability over minutes and hours, FENO is elevated in children with asthma 
during periods when grass pollen exposure is present 
41,56
 and also is elevated during the 
autumn (when moulds cast spores) for those exposed to indoor moulds 
43
.  Children with 
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hayfever have elevated FENO
6564 
and concentrations become particularly elevated during 
the spring when compared to those without hayfever 
43
.  In addition to the factors 
described in table 4 and figure 12, intrasubject variability in FENO measurements may 
also be introduced by the apparatus itself.  As with all analytical processes, there is 
variability in repeated measurements using the same apparatus and this variability can be 
reduced by measuring two or three FENO values and reporting the mean value 
20
 but this 
requires time and also costs money.  Further apparatus-dependent variability arises when 
different methods to derive NO are used; one study found an intrasubject difference of 
4ppb between devices made by the same manufacturer
6665
.  Intrasubject variability 
becomes considerably greater when apparatus from different manufacturers are used
6766
 
where a typical difference might be 8ppb but range between -12 and +28ppb.  At present 
it seems sensible to make repeated measurements for a given individual using the same 
apparatus.  
 
3.2 Trials were confounded by poor adherence with inhaled corticosteroid treatment. 
Adherence to ICS treatment is crucial to the interpretation of elevated FENO, as it 
currently is for standard symptom-based asthma management.  Elevated FENO is 
associated with poor asthma control 
41-43
 and poor adherence with ICS treatment 
26,6826,67
, 
whereas increasing ICS treatment leads to reduced FENO 
6867
.  Adherence to treatment is 
always a challenge to measure in asthma, one paper found that typical FENO 
concentrations for adolescents with adherence was >50% was 24 ppb and was 31ppb for 
those with <50% compliance 
26
.  A second study of 17 children found that compliance 
with ICS of between 75 and 100% was associated with a relative reduction in FENO of 
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50-100% whereas compliance below 75% was associated with changes in FENO of less 
that 50% 
6867
.  Observations of heterogeneity in FENO response to ICS 
69,7068,69
 might 
reflect the presence of individuals with high FENO but little airway eosinophilia, a 
phenomenon seen in adults
7170
 but not described in children, or heterogeneity in 
adherence to ICS treatment.  Although there is most likely to be incomplete adherence to 
ICS in the clinical trials, asthma outcomes improved in both FENO and standard arms of 
most trials suggesting that adherence was generally good. 
3.3 Wrong study design.  The clinical trials which have been completed in children to 
date all compared standard symptom-based treatment versus standard treatment plus 
FENO and perhaps trials should compare symptom-based treatment versus FENO only 
treatment.  This bold study design has only been used in one trial of adult patients
7271
 and 
found that FENO guided treatment was associated with reduced ICS doses and a non 
significant trend for reduced symptoms compared to symptom based management.  The 
poor correlation between asthma control and FENO reported in some studies
41-43
 and the 
lack of correlation in at least one study
47
 does question whether asthma treatment can be 
guided only by FENO.  On the one hand, FENO and symptoms measure different outcomes 
and therefore an algorithm which captures both outcomes might be better than either 
alone.  A more conservative approach might argue that there is a too much of a leap of 
faith involved in using FENO to guide treatment, and the symptom-based approach is 
patient-centred and therefore symptoms should predominate as the ultimate trigger for 
changing asthma treatment. 
3.4 Insufficient power.  Although studies justified their sample size by a power 
calculation, descriptions of the power calculations do not include a mean or median FENO 
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value and associated variability.  Pragmatically, only two one published studiesy 
randomised more than 100 children
26
 
32
 so it is possible that the remaining studies may 
have been underpowered.  
3.5 Wrong cut offs used.  Although increased FENO is associated with adverse asthma 
outcomes in children, the definition of what is “increased” remains unclear.   although 
concentrations of >35ppb in children are, by consensus, thought to be high 
34
.  Evidence 
from population Whilst there is some guidance from population based studies suggests 
that to help address the question “what is a high FENO?” concentrations of >35ppb in 
children are “high” 38 but the question “what is a significant change in FENO for an 
individual?” remains poorly understood and has been explored in detail elsewhere 7372. 
One early study suggested that a change of 4 ppb might be clinically significant
7473
 but, 
as table 4 demonstrates, there are many factors other than asthma which can acutely 
change FENO by an order of at least 4ppb.  Furthermore, a rise of 4ppb might be 
important in a child whose previous FENO was 10ppb but not for a second individual 
whose FENO was 20ppb and relative change in FENO seems a more meaningful method 
for interpreting repeated measurements.   More Rrecent studies in adults have suggested 
that rather than a relative change of <30% is unlikely to be clinically relevant 
7574
 and a 
change from poor control to good control was associated with a FENO reduction of greater 
than 35% 
7675
.  Having a “significant” magnitude of change in FENO of 30-35% would be 
consistent with a clinically meaningful change in bronchial hyperreactivity (a hallmark 
for asthma and correlated with FENO) of half a doubling dose 
7776
.  Variability in repeated 
measurements of FENO may be greater in children compared with adults.  For example, 
Iin one  study of children, a FENO rise of 60% from baseline (with 95% confidence 
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intervals of approximately 25, 140) was associated with an exacerbation  where daily 
FENO measurements were made over 30 weeks observed that FENO rose by 60% (with 
95% confidence intervals of approximately 25, 140) during an exacerbation 
6352
 and by 
extrapolation, a rise in FENO of less than 60% might be indicative of increasing 
symptoms. A clinical practical guideline published by the American Thoracic Society in 
2011 
38
 acknowledged a weak evidence base and cautiously recommended that a rise in 
FENO of >20% or (in children) >20ppb may be significant and that a minimally important 
reduction in FENO was >20% for those with a FENO of ≥50ppb and <10ppb for those for 
those with lower values.  Although current guidelines consider changes in FENO 
expressed as an absolute figure or relative (percentage) change
34
, Iin the adult literature 
there has been interest in expressing FENO as a percentage of predicted but this option is 
losing favour, mostly due to lack of precision and to differences between reference 
populations raising the question of which reference is the best for a given population? A 
fourth method to express FENO is a as percentage of lowest value and is measured after a 
two week course of oral corticosteroids, but this has an associated morbidity, might yield 
a low FENO value which cannot be achieved with ICS treatment and should be reserved 
for use only in special cases under expert supervision. Of the four methods described, 
percentage difference seems best suited for individualising treatment since this recognises 
the relatively wide range of values within a population of children.    
3.6 Insight into intrasubject variability. One recent study has given insight into the 
question “what is a significant change in FENO?” 
43
.  178 children were recruited, of 
whom 47 had asthma, in a community-based observational study where FENO was 
measured over six two-month intervals.  The difference between paired FENO 
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measurements was expressed as an absolute value and limits of agreement. As might be 
expected, the limits of agreement for paired FENO measurements were greater for those 
with higher initial concentrations.  Average FENO values were stable over eight months 
but did become significantly higher over a ten month interval, presumably due to the 
children becoming taller.  Asthma was associated with elevated FENO in this population 
(27ppb versus 10 ppb for non asthmatic) but when both time and baseline FENO value 
were considered, asthma was not independently associated with change in FENO value. 
As a rough rule of thumb, the authors suggested that FENO values may rise by up to 200% 
of the previous measurements over two to four months, independently of asthma.  For 
example, in the 40 children with initial FENO between 11 and 20 ppb (median value 
14ppb) the upper limits of agreement for measurements taken at a two and four month 
interval were +22ppb and +14 ppb respectively.  As might be expected over time (and 
regression to the mean), low initial FENO concentrations became higher whilst higher 
concentrations became lower; thus the lower limits of agreement over two and four 
months for children whose initial FENO was 21-30 ppb were -19 and -25ppb.  In keeping 
with the suggestion that a more permissive approach to interpretation of FENO values, a 
more liberal algorithm which allowed FENO concentrations to rise by up to 100% (from 
16 to 29ppb) was found to be effective in reducing exacerbations and improving quality 
of life among pregnant women 
78
. 
In addition to describing variability in FENO over time, this study related FENO to asthma 
control (both present and future) and also to environmental exposures which might affect 
FENO values 
43
.  There was weak correlation between FENO and current and future asthma 
control measured over a four month interval (correlation coefficient approximately 0.2).  
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Compared with maintained good asthma control over two months, children who were 
poorly controlled but became well controlled had elevated FENO; in contrast, neither 
those who had good asthma control which became poorly controlled nor those whose 
asthma control remained poor had elevated FENO.  These observations suggested that 
elevated FENO is an index of poor current control but not poor control in two month’s 
time.  Additionally the findings suggested that the mechanism for persistently poorly 
controlled symptoms in children with asthma may not involve eosinophilic airway 
inflammation. 
 
Future research directions - so where do we go beyond 2014 with FENO? 
It is too early to consign FENO to the dust bin where failed biomarkers for asthma are 
placed.  There is still sufficient evidence to indicate that FENO may have a role in helping 
to address the current situation where there are too many children treated with 
inappropriately high doses of inhaled corticosteroids and conversely, too many children 
with poorly controlled asthma whose quality of life can be improved with ICS treatment. 
The inconsistency between the epidemiology and mechanistic studies (supportive of a 
role for FENO in asthma management) and the clinical trials to date (which are generally 
not supportive of adding FENO to standard symptom-based management) suggests either 
FENO lacks precision or we have not properly understood how to interpret FENO as a 
clinical tool. Time will show whether FENO does have role or not in the management of 
childhood asthma.  If FENO does prove to have a role in the management of childhood 
asthma then clinicians will have to place trust in FENO since guidelines will have to use 
FENO to step treatment down as well as up.  Now that insight is being gained into what 
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merits a significant change in FENO, clinical trials are needed which test these percent of 
baseline cut offs to treatment algorithms.  Future clinical trials designed to use FENO to 
improve asthma outcomes might consider the following: 
1. Comparing symptom based management and FENO only based management.  This 
might follow in the success of trials comparing symptoms versus FENO plus 
symptoms; the apparent failure of previous studies will understandably make 
clinicians very cautious in using only FENO to guide treatment.   
2. Careful attention to treatment adherence.  This needs to be integral to clinical 
trials since poor adherence has great potential to mask any true clinical benefit but 
in the long term, FENO may prove to give the clinician insight into adherence.   
3. What is the “best” outcome.  At present, the evidence would suggest that FENO 
may have a greater influence in reducing exacerbations rather than improving 
day-to-day control of symptoms.  It is possible that one algorithm may lead to 
better control and another to fewer exacerbations for a given individual. On a 
practical note, having symptom control as an outcome and part of the algorithm is 
a potential flaw in study design. 
4. Absolute versus relative FENO values.  There is sufficient evidence to categorise 
individuals as having high FENO on study entry but more work is required in 
establishing whether cut offs for second and subsequent FENO values should be 
absolute or percent of previous values.  
5. Algorithms could use FENO to guide treatment step up options for individuals with 
uncontrolled asthma despite compliance with ICS treatment, i.e. to further 
increase ICS or use alternative “add ons”, as has been applied in adults78. 
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5.6.Algorithms could use FENO to step down ICS treatment, even when (non-
asthmatic) symptoms are present. 
6.7.Clinical setting. Childhood asthma is a condition which is mostly managed in the 
community and trial design should ideally reflect this and aspire to an ideal of 
easily delivered personalised treatment algorithms 
7.8. Preschool children. Methodologies are required to allow FENO to be measured in 
younger children – currently FENO can be measured in children aged 5-6 years  
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Table 1.  Clinically important questions in asthma management where FENO may give 
insight 
 
Are these asthmatic symptoms in this child with asthma? 
Should treatment be stepped up with inhaled corticosteroids or alternative medications? 
When is it appropriate to step down inhaled corticosteroid treatment? 
When is it safe to stop treatment with inhaled corticosteroids? 
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Table 2.  Summary of the literature suggesting that exhaled nitric oxide (FENO) may or 
may not be a good biomarker for childhood asthma. 
Studies suggesting FENO may be a good 
biomarker for childhood asthma 
Studies suggesting FENO may NOT be a good 
biomarker for childhood asthma 
FENO is elevated in children with asthma 
13
 
 
FENO is elevated in atopic non-asthmatic 
children 
45
 
7978
 and in adolescents whose 
asthma has remitted 
8079
 
Exhaled nitric oxide is positively correlated 
with threewo hallmarks for asthma, sputum 
eosinophils 
44,81,8244,80,81
 (r=0.5),  FEV1
44
and 
and bronchial hyperresponsiveness (BHR) 
45
 
46
  
 
Exhaled NO is not related to FEV1 
45
 or 
BHR 
48
  
Exhaled nitric oxide is positively correlated 
with airway eosinophilia after two weeks 
treatment with oral corticosteroids (r=0.5) 
10
 
 
Elevated FENO is associated with poor 
asthma control (r=0.2) 
41-43
 
FENO is not correlated with asthma control
47
 
 
FENO rises after withdrawal of ICS and 
before symptoms relapse
18
 
FENO does not predict relapse after ICS 
withdrawal 
8382
 
Treatment with inhaled corticosteroids reduces 
FENO in children with asthma 
6867
.   
FENO remains elevated in some individuals 
despite treatment with ICS 
84,8583,84
.   
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Table 3.  Details of the six randomised controlled trials comparing standard symptom-based asthma management against standard 
management plus exhaled nitric oxide (FENO) in children with asthma.  *presented as abstract and additional data provided by Prof 
Chang (personal communication). 
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Study Population details FENO Cut 
off(s) used  
Study design Primary outcome Secondary outcomes 
de Jongste
32
 Aged 6-18 attending 
academic centres or 
hospitals.  Atopic (by 
plasma IgE or skin 
prick test). Stable 
mild-moderate 
asthma.  151 
randomised. 
≥20 ppb for 
6-10 year 
olds 
≥25 ppb for 
>10 year olds 
30 week study, 
intervention arm 
made daily FENO 
measurements. 
Treatment 
reviewed each 3 
weeks by 
telephone, 
physiological 
testing 1, 3, 5 
months and at end 
of study 
Symptom free days 
during last 3 months 
of trial; this 
improved equally in 
both arms of the 
trial.  
No difference between control and 
intervention arm for ICS dose, 
FEV1, FENO or exacerbations.  
Peirsman
33
 Age range not stated.  
Mild to severe asthma 
attending hospital 
clinics. Atopic (by 
plasma IgE or skin 
prick testing).  99 
randomised 
≥20 ppb 52 week study.  
FENO and 
symptoms 
reviewed every 
three months 
Symptom free days; 
no difference 
between groups 
Exacerbation; reduced in 
intervention arm (18/49) compared 
to the control arm (35/50). 
Fritsch
27
 Aged 6-18 years. 52 
randomised.Attending 
hospital clinic.  Skin 
prick positive.  
Greater than  
or ≤20ppb 
6 month duration, 
assessed each 6 
weeks 
FEV1 – no 
difference 
Exacerbations, mid expiratory 
flows, control.  Mid expiratory 
flow 11 % higher in FENO group.  
Increased ICS doses (200 
microg/day) in FENO group.  
Petsky* 
31
 Aged >4 years 81 
children invited 63 
randomised.  
Attending hospital 
clinic.  
≥ or less than 
10 ppb for 
non atopic 
children 
≥ or less than 
12 month study, 
monthly visits for 
four months and 
alternate months 
thereafter.  
Exacerbation – 
FENO associated 
with reduced 
exacerbations (19% 
versus 47%) 
Quality of life and spirometry did 
not significantly differ between 
groupsalso improved marginally.  
Spirometry unchanged. 
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12 ppb with 
one positive 
skin test 
≥ or less than 
20 ppb with 
more than 
one positive 
skin test 
Pijnenberg
30
 
 
Aged 5-18 years.  108 
screened 89 
randomised. 
Attending hospital 
clinic. Atopic asthma 
treated with ICS.  
Less than or 
≥30ppb 
12 month study 
with assessments 
each 3 months 
ICS dose.  No 
difference between 
groups. 
FENO group had improved PD20 
(1.3 doubling doses), lower FENO 
(geometric mean difference at end 
of study 32% lower) and trend for 
fewer exacerbations (20% versus 
39%) 
Pike
28
 Aged 6-17 years. 96 
screened, 90 
randomised.  
Attending hospital 
clinic with moderate-
severe asthma.   
≤15ppb 
15.1-24.9ppb 
≥25 ppb 
12 month study, 
assessed each 2 
months 
ICS dose and 
exacerbation.  No 
difference between 
groups. 
Spirometry, no difference between 
groups. 
Szeffler
26
 Aged 12-20 years.  
780 screened.  546 
randomised. Inner 
city area where ≥20% 
households below 
poverty level.  
0-20 
20.1-30 
30.1-40 
>40 
46 week duration 
assessments each 
6-8 weeks 
Number of days 
with symptoms.  No 
difference between 
FENO and control 
groups 
FENO group had:  
Mean increased fluticasone 
treatment 119 microg/day. 
10% reduction in proportion 
requiring OCS 
Among obese children 0.6 fewer 
days with symptoms.  For those 
with multiple positive skin tests (ie 
>9 out of 14 tested) 0.8 fewer days 
with symptoms.  
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Verini
29
 Aged 6-17 years.  64 
children. Referred to 
hospital and admitted. 
12 12 month study 
with assessments 
at baseline and 
after 6 and 12 
months 
Severity score 
(mean reduced 
significantly from 
1.1 to 0.6 and 0.8 
after 6 and 12 
months only in the 
FENO group).  
Exacerbation (mean 
number reduced 
from 2.0 to 1.0 and 
0.8 only in FENO 
group), treatment 
(unchanged in FENO 
group but some 
evidence of 
increased treatment 
in control arm). 
Spirometry – no difference 
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Table 4.  Factors which are associated with changes in FENO in children independent of 
asthma 
 
Factor Approximate magnitude of effect 
Height Up to 1ppb rise per cm height gained 
24
 
Dietary exposures Short lived rise of up to 5-10ppb 
53,54
 
Allergen exposure Rise of up to 50% during birch pollen 
season 
56
 
Exposure to second hand smoke Reduction of 100% (26ppb for exposed 
children versus 56ppb)  
57
 or  absolute 
reduction of 10ppb 
58
 
Asthma exacerbation Typical rise of approximately 60% 
41
 
Exposure to poor outdoor air quality Rise of approximately 1ppb 4 hours after 
each increase of 10mg/m
3
 fine particulate 
exposure (PM2.5) 
59
 
Genetic variations Variations in genes coding for NOS2 and 
NOS3 may lead to differences in FENO in 
adults of 10% 
8685
 or 10ppb 
8786
 but no 
association found for NOS1 variant and 
FENO in children 
8887
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FIGURE LEGENDS 
Figure 1.  Diagram demonstrating the flow dependence of exhaled nitric oxide (FENO).  
At lower flows, concentrations are higher and vice versa.  The figure also demonstrates 
how the absolute FENO value is derived from a plateau achieved over a ten second 
exhalation in older children and adults (six seconds in younger children). 
 
Figure 12.  Summary of the asthma-dependent and independent factors associated with 
increased or reduced concentrations of exhaled nitric oxide (FENO). 
Figure 2.  A forest plot comparing the effect on exacerbations requiring oral 
corticosteroid treatment where maintenance treatment is driven by exhaled nitric oxide 
(ENO) and symptoms versus symptoms alone. 
Figure 3. A forest plot comparing the effect on inhaled corticosteroid dose at  the time of 
study exit where maintenance treatment is driven by exhaled nitric oxide (ENO) and 
symptoms versus symptoms alone. 
 
